Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings data on Tuesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.17) by $0.03.
Sunesis Pharmaceuticals, Inc. logo Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by investment analysts at Wedbush from an �outperform� rating to a �neutral� rating in a note issued to investors on Friday, TheFlyOnTheWall.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) plummeted 3.73 percent to $7.49 in the last trading session after Wedbush cut its ratings for the biopharmaceutical company from �Outperform� to �Neutral� in a research report sent to investors on August 29.
Yesterday, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) saw four of its insiders complete stock dispositions. The first three insiders to unload stock were James Barrett, Patrick Kerins, and Peter Barris, all of whom own over 10% of the company.